Author

Nisha Joseph

Institutions: Emory University, Winship Cancer Institute

Observed institutions: Emory University, Winship Cancer Institute

OpenAlex ID: A5124938711

Iberdomide plus daratumumab and dexamethasone versus daratumumab, bortezomib, and dexamethasone in patients with relapsed or refractory multiple myeloma (EXCALIBER-RRMM): an open-label, randomised, controlled, phase 3 trial

2026 · Sagar Lonial, Meletios A Dimopoulos, et al. · The Lancet Oncology

Works count: 1

Citation count:

H-index:

I10-index: